TABLE 3.
Summary table of the present study results and orthokeratology (OK) myopia control trials and retrospective clinical reports, 2010 to present
| Study | Location | Age (y) | n (OK) | Mean RE at baseline (D) | Mean AL at baseline (mm) | AL increase (mm/y) | Type | |
|---|---|---|---|---|---|---|---|---|
| OK group | Control group | |||||||
| Santodomingo-Rubido et al.16 | Spain | 6–12 | 61 (31) | −2.05 | 24.39 | 0.02 | 0.38 | CT |
| Charm and Cho13 | China | 8–11 | 28 (12) | −6.41 | 26.05 | 0.06 | 0.30 | CT |
| Pauné et al.17* | Spain | 10–15 | 35 (35) | −2.80 | 24.61 | 0.08 | O | |
| Jakobsen and Moller18 | Denmark | 6–12 | 60 (30) | −2.00 | 24.12 | 0.09 | 0.28 | CT |
| Kakita et al.9 | Japan | 8–16 | 92 (42) | −2.55 | 24.66 | 0.15 | 0.30 | CT |
| Chen et al.12 | China | 6–12 | 80 (43) | −2.46 | 24.37 | 0.15 | 0.36 | CT |
| Pauné et al.19 | Spain | 9–16 | 100 (29) | −3.44 | 24.77 | 0.15 | 0.28 | CT |
| Pauné et al.17* | Spain | 10–15 | 36 (36) | −3.41 | 24.69 | 0.16 | O | |
| Zhu et al.20 | China | 7–14 | 128 (65) | −4.29 | 24.91 | 0.16 | 0.39 | O |
| Guo et al.21 | China | 6–11 | 70 (70) | −2.62 | 24.45 | 0.17 | n/a | CT |
| Present study | Berkeley, CA | 5–18 | 102 (102) | −2.54 | 24.51 | 0.18 | O | |
| Qi et al.22 | China | 8–15 | 73 (73) | −3.22 | 24.86 | 0.18 | O | |
| Hiraoka et al.23 | Japan | 8–12 | 59 (29) | −1.89 | 24.09 | 0.19 | 0.38 | O |
| Lin et al.24 | China | 8–14 | 1176 (588) | −2.83 | 24.87 | 0.19 | 0.31 | O |
| Cho and Cheung8 | China | 6–10 | 78 (37) | −2.12 | 24.48 | 0.20 | 0.37 | CT |
| He et al.25 | China | 7–12 | 271 (141) | −2.74 | 24.71 | 0.27 | 0.38 | O |
*Two different lens types from the same clinical study. Age = age range; AL = axial length; n = number of subjects; (OK) = subjects treated with orthokeratology lenses; RE = refractive error; Type = type of trial (CT = prospective clinical trial; O = retrospective observational clinical study).